title: [The quantitative evaluation of mutation V617F of gene JAK2 under chronic myeloproliferative diseases].
abstract: The mutation V617F of gene JAK2 is detected in 95% of patients with genuine polycythemia, in 50% of patients with essential thrombocytemia and idiopathic myelofibrosis. The mutation V617F can be applied as a molecular marker of response to treatment in patients with chronic myeloproliferative diseases associated with this mutation. The technique of quantitative evaluation of V617F (sensitivity up to 0.01%) using polymerase chain reaction is described. This method can be applied to assess the minimal residual disease in patients with chronic myeloproliferative diseases.
authors.forename: A O
authors.initials: AO
authors.lastname: Abdullaeva
authors.forename: O A
authors.initials: OA
authors.lastname: Glinshchikova
authors.forename: S A
authors.initials: SA
authors.lastname: Suslova
authors.forename: N Kh
authors.initials: NKh
authors.lastname: Shadieva
authors.forename: L Iu
authors.initials: LIu
authors.lastname: Kolosova
authors.forename: L M
authors.initials: LM
authors.lastname: Meshcheriakova
authors.forename: M V
authors.initials: MV
authors.lastname: Vakhrusheva
authors.forename: A B
authors.initials: AB
authors.lastname: Sudarikov
mesh_terms: D000293:Adolescent; D000328:Adult; D000368:Aged; D000369:Aged, 80 and over; D002460:Cell Line; D002648:Child; D002908:Chronic Disease; D005069:Evaluation Studies as Topic; D006801:Humans; D053614:Janus Kinase 2 / Q000097:blood* / Q000235:genetics; D008875:Middle Aged; D009154:Mutation; D009196:Myeloproliferative Disorders / Q000097:blood* / Q000235:genetics; D011086:Polycythemia / Q000097:blood / Q000235:genetics; D055728:Primary Myelofibrosis / Q000097:blood / Q000235:genetics; D013920:Thrombocythemia, Essential / Q000097:blood / Q000235:genetics
chemical_list: C507924:JAK2 protein, human; D053614:Janus Kinase 2